Literature DB >> 11106587

Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

C Kuperwasser1, G D Hurlbut, F S Kittrell, E S Dickinson, R Laucirica, D Medina, S P Naber, D J Jerry.   

Abstract

Breast cancer is the most frequent tumor type among women in the United States and in individuals with Li-Fraumeni syndrome. The p53 tumor suppressor gene is altered in a large proportion of both spontaneous breast malignancies and Li-Fraumeni breast cancers. This suggests that loss of p53 can accelerate breast tumorigenesis, yet p53-deficient mice rarely develop mammary tumors. To evaluate the effect of p53 loss on mammary tumor formation, the p53(null) allele was back-crossed onto the BALB/c genetic background. Median survival was 15.4 weeks for BALB/c-p53(-/-) mice compared to 54 weeks for BALB/c-p53(+/-) mice. Sarcomas and lymphomas were the most frequent tumor types in BALB/c-p53(-/-) mice, whereas 55% of the female BALB/c-p53(+/-) mice developed mammary carcinomas. The mammary tumors were highly aneuploid, frequently lost the remaining wild-type p53 allele, but rarely lost BRCA1. Although mammary tumors were rarely detected in BALB/c-p53(-/-) female mice, when glands from BALB/c-p53(-/-) mice were transplanted into wild-type BALB/c hosts, 75% developed mammary tumors. The high rate of mammary tumor development in the BALB/c background, but not C57Bl/6 or 129/Sv, suggests a genetic predisposition toward mammary tumorigenesis. Therefore, the BALB/c-p53(+/-) mice provide a unique model for the study of breast cancer in Li-Fraumeni syndrome. These results demonstrate the critical role that the p53 tumor suppressor gene plays in preventing tumorigenesis in the mammary gland.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106587      PMCID: PMC1885755          DOI: 10.1016/S0002-9440(10)64853-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Radiation-induced cytogenetic instability in vivo.

Authors:  R L Ullrich; C M Davis
Journal:  Radiat Res       Date:  1999-08       Impact factor: 2.841

2.  Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment.

Authors:  C Kuperwasser; J Pinkas; G D Hurlbut; S P Naber; D J Jerry
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

3.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

Review 4.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.

Authors:  R D Cardiff; M R Anver; B A Gusterson; L Hennighausen; R A Jensen; M J Merino; S Rehm; J Russo; F A Tavassoli; L M Wakefield; J M Ward; J E Green
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

5.  Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation.

Authors:  R L Ullrich; N D Bowles; L C Satterfield; C M Davis
Journal:  Radiat Res       Date:  1996-09       Impact factor: 2.841

6.  Genetic background alters the spectrum of tumors that develop in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; A Bradley; L A Donehower
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

7.  Database of p53 gene somatic mutations in human tumors and cell lines.

Authors:  M Hollstein; K Rice; M S Greenblatt; T Soussi; R Fuchs; T Sørlie; E Hovig; B Smith-Sørensen; R Montesano; C C Harris
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

8.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

9.  A subset of p53-deficient embryos exhibit exencephaly.

Authors:  V P Sah; L D Attardi; G J Mulligan; B O Williams; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  75 in total

1.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Authors:  Jason I Herschkowitz; Wei Zhao; Mei Zhang; Jerry Usary; George Murrow; David Edwards; Jana Knezevic; Stephanie B Greene; David Darr; Melissa A Troester; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

2.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

3.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.

Authors:  L Sivaraman; O M Conneely; D Medina; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

4.  Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis.

Authors:  Jennifer L Avila; Oliver Grundmann; Randy Burd; Kirsten H Limesand
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-01       Impact factor: 7.038

Review 5.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

6.  Distinct roles of the three Akt isoforms in lactogenic differentiation and involution.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Ina Klebba; Charlotte Kuperwasser; Philip N Tsichlis
Journal:  J Cell Physiol       Date:  2008-11       Impact factor: 6.384

7.  Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.

Authors:  L Cheng; Z Zhou; A Flesken-Nikitin; I A Toshkov; W Wang; J Camps; T Ried; A Y Nikitin
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

8.  Role of JNK in a Trp53-dependent mouse model of breast cancer.

Authors:  Cristina Cellurale; Claire R Weston; Judith Reilly; David S Garlick; D Joseph Jerry; Hayla K Sluss; Roger J Davis
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

9.  IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter.

Authors:  G C Mitchell; J L Fillinger; S Sittadjody; J L Avila; R Burd; K H Limesand
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

10.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Authors:  Karlyne M Reilly; Robert G Tuskan; Emily Christy; Dagan A Loisel; Jeremy Ledger; Roderick T Bronson; C Dahlem Smith; Shirley Tsang; David J Munroe; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.